2022 ASCO Annual Meeting*

With an extended follow-up of approximately 5 years, durable clinical benefit with no new safety concerns was observed with nivolumab ± ipilimumab for patients with MSI-H/dMMR metastatic CRC.

Single-arm study shows preliminary activity of trastuzumab deruxtecan in advanced HER2-positive biliary tract cancers, including for HER2-low disease.

Addition of radiotherapy to chemotherapy significantly improved the R0 resection rate specifically in patients who underwent surgery after chemoradiotherapy or chemotherapy alone but not in the overall population of patients with unresectable locally advanced pancreatic cancer.

Improved survival with nivolumab + chemotherapy and nivolumab + ipilimumab vs chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma and at least 1% PD-L1 expression assessed by either tumor cell staining or CPS.

Compared with sorafenib treatment alone, addition of a single dose of tremelimumab to durvalumab in STRIDE and durvalumab monotherapy were associated with meaningful, patient-centered benefits for patients with unresectable hepatocellular carcinoma.

In addition to a previously reported overall survival benefit, durvalumab + gemcitabine/cisplatin was associated with a trend toward longer time to deterioration in global health status/quality of life for patients with advanced biliary tract cancer vs placebo + gemcitabine/cisplatin.

The phase III PARADIGM trial demonstrated superior overall survival with first-line panitumumab vs bevacizumab in combination with mFOLFOX6 in both the left-sided and overall mCRC populations with WT RAS.

Intensification of first-line chemotherapy with mFOLFOXIRI in combination with panitumumab did not improve response rate, depth of response, or PFS in patients with RAS and BRAF wild-type mCRC.

Among patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAF^V600E-mutated primary tumors, FOLFOXIRI + bevacizumab was associated with superior outcomes vs FOLFOX or FOLFIRI + bevacizumab with an increase in manageable toxicity.

Early data showed that among 14 patients with locally advanced, dMMR rectal cancer who completed treatment with the PD-1 inhibitor dostarlimab, all 14 achieved a clinical complete response, without the need for chemoradiotherapy or surgery.